Angel Yang
Family · Spartanburg, SCNPI 1710690979
Payments from drug & device makers
Across 265 payments — averaging $25.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$1K
- AstraZeneca$864
- Regeneron Healthcare Solutions, Inc.$579
- GSK$529
- United Therapeutics Corporation$482
- Sanofi$471
- plus $3K from 23 others
What the payments were for
- Travel & lodging$1,08916%
- Food & beverage$5,49480%
- Education$2514%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 6 | $1,154 |
| AstraZeneca(2 entities) | 30 | $864 |
| Regeneron Healthcare Solutions, Inc. | 25 | $579 |
| GSK | 40 | $529 |
| United Therapeutics Corporation | 20 | $482 |
| Sanofi | 15 | $471 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $318 |
| Electromed, Inc. | 24 | $309 |
| Verona Pharma, Inc. | 19 | $283 |
| ANI Pharmaceuticals, Inc. | 3 | $270 |
| Amgen | 15 | $247 |
| Boehringer Ingelheim | 10 | $205 |
| Actelion Pharmaceuticals US, Inc. | 4 | $190 |
| Insmed, Inc. | 7 | $129 |
| Mallinckrodt Hospital Products Inc. | 5 | $123 |
| Axsome Therapeutics, Inc. | 4 | $121 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Mylan Specialty L.p. | 4 | $62 |
| Merck | 2 | $60 |
| Philips North America LLC | 3 | $54 |
| Hikma Pharmaceuticals USA | 3 | $49 |
| Grifols USA, LLC | 2 | $46 |
| Baxter Healthcare | 2 | $42 |
| Viatris Specialty LLC | 2 | $37 |
| Inogen, Inc. | 2 | $35 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Chiesi USA, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,834 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 796 | $664,896 |
| UptraviSelexipag | 11 | $256,365 |
| OfevNintedanib Esylate | 11 | $140,363 |
| ZemairaAlpha-1-Proteinase Inhibitor | 34 | $126,313 |
| Dupixent PenDupilumab | 22 | $88,418 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 112 | $84,298 |
| Breo ElliptaFluticasone/Vilanterol | 140 | $70,458 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 90 | $53,089 |
| Spiriva RespimatTiotropium Bromide | 61 | $37,800 |
| SymbicortBudesonide/Formoterol Fumarate | 98 | $32,782 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 41 | $25,843 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 753 | $22,313 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $12,831 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 79 | $12,233 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $11,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $529 | $804,4661,057 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi | $190 | $256,36511 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $205 | $216,837126 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $864 | $117,080210 claims |
| MerckDulera | $60 | $11,36618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.
Other family in Spartanburg
- Ashley McKinneySpartanburg$16K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.